title: Angiotensin II type 2 receptor blockade amplifies the early signals of cardiac growth response to angiotensin II in hypertrophied hearts.
abstract: BACKGROUND
  We have previously shown that the acute molecular growth response of new protein synthesis and protein kinase C activation in response to angiotensin II (Ang II) is altered in left ventricular (LV) hypertrophy compared with normal hearts. We have also shown an upregulation of Ang II type 2 (AT2) receptors in hypertrophied hearts relative to controls. Activation of AT2 receptors is proposed to counteract growth effects of AT1 receptor in response to Ang II. Thus, we tested the hypothesis that in hypertrophied hearts, the AT2 receptor mediates inhibitory effects on the new cardiac protein synthesis in response to acute Ang II stimulation.
  
  
  RESULTS
  Flaccid buffer-perfused adult normal and hypertrophied rat hearts were perfused with Ang II 10(-8) mol/L plus prazosin 10(-7) mol/L or Ang II plus the AT2 blocker PD 123319 5x10(-7) mol/L. New protein synthesis was measured by the rate of [3H]phenylalanine incorporation into the LV proteins. In normal hearts, Ang II (n=8) increased the rate of [3H]phenylalanine incorporation by 74+/-27% (P<0.05 versus no drug). Treatment with PD123319 (n=8) did not increase protein synthesis compared with Ang II alone (32+/-11% versus Ang II alone, P=NS). In hypertrophied hearts, Ang II alone (n=6) increased the rate of [3H]phenylalanine incorporation only by 23+/-13% (P=NS versus no drug). In contrast, treatment with PD123319 (n=7) induced a 76+/-21% increase in new LV protein synthesis compared with Ang II alone (P<0.05). AT2 receptor blockade in Ang II-stimulated hypertrophied hearts was associated with enhanced membrane protein kinase C translocation and reduced LV cGMP content.
  
  
  CONCLUSIONS
  These data support the hypothesis that in adult hypertrophied rat hearts, inhibition of cardiac AT2 receptors, which are upregulated in chronic LV hypertrophy, amplifies the immediate LV growth response to Ang II. This appears to be related to augmented Ang II-stimulated PKC activation and suppression of cGMP signaling.
authors.affiliation: Cardiovascular Division, The Harvard Thorndike Laboratory, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Mass 02115, USA.
authors.forename: J
authors.initials: J
authors.lastname: Bartunek
authors.forename: E O
authors.initials: EO
authors.lastname: Weinberg
authors.forename: M
authors.initials: M
authors.lastname: Tajima
authors.forename: S
authors.initials: S
authors.lastname: Rohrbach
authors.forename: B H
authors.initials: BH
authors.lastname: Lorell
mesh_terms: D000804:Angiotensin II; D057911:Angiotensin Receptor Antagonists; D000818:Animals; D006332:Cardiomegaly / Q000188:drug therapy*; D006152:Cyclic GMP / Q000378:metabolism; D004353:Drug Evaluation, Preclinical; D004789:Enzyme Activation; D006352:Heart Ventricles / Q000378:metabolism; D066298:In Vitro Techniques; D008297:Male; D010649:Phenylalanine / Q000378:metabolism; D014176:Protein Biosynthesis; D011493:Protein Kinase C / Q000187:drug effects; D051381:Rats; D017208:Rats, Wistar; D044139:Receptor, Angiotensin, Type 2; D015398:Signal Transduction / Q000187:drug effects*
chemical_list: D057911:Angiotensin Receptor Antagonists; D044139:Receptor, Angiotensin, Type 2; D000804:Angiotensin II; D010649:Phenylalanine; D011493:Protein Kinase C; D006152:Cyclic GMP